Last reviewed 2026-04-20 · How we verify

COVID-19 vaccine, low dose level

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site pain
• Fatigue
• Headache
• Myalgia
• Injection Site Pain
• Arthralgia
• COVID-19
• Lymphadenopathy
• Malaise
• Chills
• Diarrhoea
• Injection site erythema

Key clinical trials

• A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
• A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection (PHASE1, PHASE2)
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
• A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19 (PHASE1, PHASE2)
• Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (PHASE1)
• Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults (PHASE1, PHASE2)
• The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus (PHASE1)
• A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• COVID-19 vaccine, low dose level CI brief — competitive landscape report
• COVID-19 vaccine, low dose level updates RSS · CI watch RSS
• Rokote Laboratories Finland Oy portfolio CI